TAKEDA PHARMACEUTIC-SP ADR (TAK) Earnings History & Surprises
NYSE:TAK • US8740602052
18.21 USD
+0.14 (+0.77%)
At close: Mar 10, 2026
18.21 USD
0 (0%)
After Hours: 3/10/2026, 8:04:00 PM
Past quarterly earnings results for TAKEDA PHARMACEUTIC-SP ADR (TAK), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMay 13, 2026
PeriodQ4 / 2026
EPS Estimate-¥7
Revenue Estimate1.119T
Last Reported
Release DateJan 30, 2026
PeriodQ3 / 2026
EPS Reported¥33
EPS Surprise 90.61%
Revenue Surprise 0.21%
Beat Rate
50%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (JPY)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2026 | 32.81 | 17.21 | 90.61% | 341.77% | 1.192T | 1.189T | 0.21% | 4.16% |
| Q2 2026 | -3.74 | 17.06 | -121.92% | -112.87% | 1.113T | 1.184T | -6.04% | -5.38% |
| Q1 2026 | 39.68 | 28.56 | 38.94% | 30.79% | 1.107T | 1.187T | -6.76% | -8.39% |
| Q4 2025 | -32.66 | -27.88 | -17.13% | -3,151.24% | 1.053T | 1.076T | -2.10% | 0.24% |
| Q3 2025 | 7.43 | 12.71 | -41.58% | -78.01% | 1.144T | 1.15T | -0.48% | 2.96% |
| Q2 2025 | 29.05 | 16.56 | 75.50% | 287.55% | 1.176T | 1.106T | 6.35% | 12.75% |
| Q1 2025 | 30.34 | 22.09 | 37.34% | 5.56% | 1.208T | 1.104T | 9.45% | 14.11% |
| Q4 2024 | -1.00 | 0.39 | -357.78% | -110.03% | 1.051T | 916.958B | 14.60% | 9.91% |
| Q3 2024 | 33.78 | 14.38 | 134.84% | -11.88% | 1.111T | 1.017T | 9.24% | 1.33% |
| Q2 2024 | -15.49 | 18.39 | -184.23% | -177.99% | 1.043T | 1.009T | 3.34% | 4.07% |
| Q1 2024 | 28.74 | 34.92 | -17.69% | -15.35% | 1.059T | 992.223B | 6.69% | 8.86% |
| Q4 2023 | 10.01 | 6.78 | 47.57% | 388.22% | 956.156B | 966.415B | -1.06% | 9.49% |
| Q3 2023 | 38.33 | 37.62 | 1.89% | 107.24% | 1.097T | 1.015T | 8.05% | 21.66% |
| Q2 2023 | 19.86 | 19.30 | 2.91% | 35.93% | 1.002T | 962.035B | 4.19% | 18.64% |
| Q1 2023 | 33.95 | 35.90 | -5.43% | -22.76% | 972.465B | 934.47B | 4.07% | 2.41% |
| Q4 2022 | -3.47 | 3.01 | -215.36% | -105.51% | 873.289B | 847.458B | 3.05% | 13.37% |
| Q3 2022 | 18.50 | 25.53 | -27.54% | -37.36% | 901.294B | 846.517B | 6.47% | 7.71% |
| Q2 2022 | 14.61 | 23.87 | -38.79% | 1,229.27% | 844.82B | 825.266B | 2.37% | 7.08% |
| Q1 2022 | 43.96 | 33.97 | 29.40% | 66.19% | 949.603B | 873.46B | 8.72% | 18.43% |
| Q4 2021 | 63.01 | 24.19 | 160.51% | 11,362.22% | 770.274B | 791.881B | -2.73% | -0.19% |
| Q3 2021 | 29.53 | 21.90 | 34.83% | 886.43% | 836.753B | 847.525B | -1.27% | -2.63% |
| Q2 2021 | 1.10 | 16.43 | -93.31% | -93.64% | 788.935B | 840.261B | -6.11% | -2.73% |
| Q1 2021 | 26.45 | 8.10 | 226.72% | 498.57% | 801.85B | 814.274B | -1.53% | -5.57% |
| Q4 2020 | 0.55 | -53.07 | 101.04% | - | 771.702B | 802.131B | -3.79% | - |
| Q3 2020 | 2.99 | -15.27 | 119.60% | - | 859.317B | 844.174B | 1.79% | - |
| Q2 2020 | 17.29 | -23.52 | 173.52% | - | 811.048B | 822.735B | -1.42% | - |
| Q1 2020 | -6.64 | -21.96 | 69.77% | - | 849.121B | 824.716B | 2.96% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-2.37%
Max EPS beat (4)
90.61%
Min EPS beat (4)
-121.92%
Revenue beat statistics
Revenue beat (4)
1
Average Revenue beat (4)
-3.67%
Max Revenue beat (4)
0.21%
Min Revenue beat (4)
-6.76%
Analysis
In the last 4 quarters, TAK has beaten EPS estimates in 2 out of 4 releases
TAK has beaten revenue estimates in 1 out of the last 4 releases
In the last 4 quarters, TAK reported -2.4% below the EPS estimates on average.
In the last 4 quarters, TAK reported -3.7% below the revenue estimates on average.
TAKEDA PHARMACEUTIC-SP ADR / TAK Earnings FAQ
What is the most recent earnings date for TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) last reported earnings on 1/30/2026.
Did TAK stock beat earnings estimates in the most recent quarter?
TAKEDA PHARMACEUTIC-SP ADR (TAK) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does TAK stock beat earnings estimates?
In the last 4 quarters, TAKEDA PHARMACEUTIC-SP ADR (TAK) has beaten EPS estimates in 2 out of 4 releases.